GeronFRA:GON +1.38%39 OCF Yield % is -14.44 as of Jul. 03, 2026. GuruFocus rates FRA:GON with a GF Score™ of 39/100 and a GF Value™ of €5.57 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,414 Biotechnology companies, Geron ranks worse than 62.09% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Geron OCF Yield % Related Terms
Geron OCF Yield % Historical Data
* Premium members only.
The historical data trend for Geron's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GON vs SPRY, PHAT, DSGN: OCF Yield % Comparison
For the Biotechnology subindustry, Geron's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geron OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Geron's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Geron's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Geron (FRA:GON) has a OCF Yield % of -14.44 as of Jul. 03, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Geron and its competitors. According to the industry distribution chart, Geron ranks #878 out of 1414 companies in the Biotechnology industry, placing it in the top 62.1%.
Is Geron's OCF Yield % too high?
Geron's current OCF Yield % is -14.44. Based on the distribution chart, Geron ranks #878 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Geron has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Geron's OCF Yield % compare to SPRY and PHAT?
According to the Biotechnology industry distribution chart, Geron ranks #878 out of 1414 companies for OCF Yield %. This places Geron in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Geron and its competitors. Geron's current OCF Yield % is -14.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geron stock overvalued right now?
Based on GuruFocus' analysis, Geron (FRA:GON) is currently considered Possible Value Trap. The stock's GF Value™ is €5.57, compared to a current price of €1.14 — trading 79.5% below its estimated fair value. The current OCF Yield % is -14.44. Geron's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Geron (FRA:GON), the current OCF Yield % is -14.44 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Geron (FRA:GON) Overvalued in 2026?
Based on GuruFocus' analysis, Geron stock appears to be undervalued.
The current stock price of €1.14 is trading 79.5% below its estimated GF Value™ of €5.57.
GuruFocus considers Geron to be Possible Value Trap.
Key valuation signals for FRA:GON:
OCF Yield %: -14.44
GF Value™: €5.57 vs. price of €1.14 (79.5% below fair value)
No single metric tells the full story. See the FRA:GON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
39GF Score
Get the complete analysis for FRA:GON
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GON has been successfully added to your 
